In contrast, the prevention of tumor-specific T-cell senescence via ATM and/or MAPK signaling inhibition combined with anti-PD-L1 checkpoint blockade can synergistically enhance anti-tumor immunity and immunotherapy in vivo [89]. The gene discussed is ATM; the disease is neoplasm.